Back to Search
Start Over
Lichen amyloidosis: towards pathogenesis-driven targeted treatment.
- Source :
-
Clinical and experimental dermatology [Clin Exp Dermatol] 2023 Mar 01; Vol. 48 (3), pp. 261-262. - Publication Year :
- 2023
-
Abstract
- Competing Interests: Conflict of interest: R.C. has served as an advisory board member, consultant and/or investigator for AbbVie, Arcutis, Arena, Argenx, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, EPI Health, Incyte, L'Oréal, National Eczema Association, Pfizer Inc., Regeneron, Sanofi and UCB, and speaker for AbbVie, Dermavant, Eli Lilly and Company, EPI Health, Incyte, LEO Pharma, Pfizer Inc., Regeneron, Sanofi and UCB.
- Subjects :
- Humans
Amyloidosis, Familial
Skin Diseases, Genetic
Subjects
Details
- Language :
- English
- ISSN :
- 1365-2230
- Volume :
- 48
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Clinical and experimental dermatology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 36763750
- Full Text :
- https://doi.org/10.1093/ced/llac102